[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.15616/BSL.2021.27.4.216

Expression of miR-29a in whole Blood of Patients with Colorectal Neoplasm

Hwang, Dasom (Department of Biomedical Laboratory Science, College of Software and Digital Healthcare Convergence, Yonsei University)
Kim, Dahye (Department of Pathology, Yonsei University Wonju College of Medicine)
Chang, Yunhee (Department of Biomedical Laboratory Science, College of Software and Digital Healthcare Convergence, Yonsei University)
Hirgo, Workneh Korma (Department of Biomedical Laboratory Science, College of Software and Digital Healthcare Convergence, Yonsei University)
Lee, Hyeyoung (Department of Biomedical Laboratory Science, College of Software and Digital Healthcare Convergence, Yonsei University)

Abstract

Colorectal cancer (CRC) is major cancer with high incidence and mortality worldwide. It is known that most CRCs arise from precursor adenomatous polyps (APs). Recently, microRNA (miRNA) has been proposed as a biomarker for various cancers including CRC. In this study, the expression patterns of miR-29a in the whole blood (WB) of CRC, AP, and control groups were analyzed by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) to evaluate the expression level of miR-29a in patients with colorectal neoplasm (CRN) including CRC and AP. As a result, the relative expression of miR-29a was significantly decreased in the patients with CRN compared to the control group (P<0.001). The results were in agreement with previous in vitro cell studies and studies that used tissue and feces samples, suggesting that miR-29a in WB may be useful in demonstrating the status of colorectal tissue. Additionally, we divided the control group into healthy control (HC) without any colorectal symptoms and non-tumor control (NTC) with colorectal symptoms but without any CRN. And then the relative expression of miR-29a was also significantly decreased in the NTC group compared to the HC group (P<0.001). Therefore, our study revealed that miR-29a can differentiate patients with CRN from HC group, but they are also involved in the early stage of inflammatory response and cannot be specific biomarkers for CRN.

Keywords

Colorectal cancer; Adenomatous polyp; Colorectal neoplasm; MicroRNA; MicroRNA-29a; Whole blood; Biomarker;

Citations & Related Records

Reference

1	Bai F, Jiu M, You Y, Feng Y, Xin R, Liu X, Mo L, Nie Y. Mir-29a-3p represses proliferation and metastasis of gastric cancer cells via attenuating has3 levels. Mol Med Rep. 2018. 17: 8145-8152.
2	Balfour Sartor R. Enteric microflora in ibd: Pathogens or commensals? Inflamm Bowel Dis. 1997. 3: 230-235. DOI
3	Bartel DP. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 2004. 116: 281-297. DOI
4	Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M, Italian Multicentre Study G. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut. 2001. 48: 812-815. DOI
5	Dey S, Udari LM, RiveraHernandez P, Kwon JJ, Willis B, Easler JJ, Fogel EL, Pandol S, Kota J. Loss of mir-29a/b1 promotes inflammation and fibrosis in acute pancreatitis. JCI Insight. 2021. 6.
6	Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. Microrna: Function, detection, and bioanalysis. Chem Rev. 2013. 113: 6207-6233. DOI
7	Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007. 104: 13780-13785. DOI
8	Gong Y, Wan JH, Zou W, Lian GY, Qin JL, Wang QM. Mir-29a inhibits invasion and metastasis of cervical cancer via modulating methylation of tumor suppressor socs1. Future Oncol. 2019. 15: 1729-1744. DOI
9	Han X, Zheng J, Wang Y, Gao Z. Mirna-29a inhibits colon cancer growth by regulation of the pten/akt/gsk3beta and wnt/beta-catenin signaling pathways. Oncol Lett. 2018. 16: 2638-2644.
10	Liu X, Lv X, Yang Q, Jin H, Zhou W, Fan Q. Microrna-29a functions as a tumor suppressor and increases cisplatin sensitivity by targeting nras in lung cancer. Technology in Cancer Research & Treatment. 2018b. 17: 1533033818758905-1533033818758905.
11	Lobionda S, Sittipo P, Kwon HY, Lee YK. The role of gut microbiota in intestinal inflammation with respect to diet and extrinsic stressors. Microorganisms. 2019. 7.
12	Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a danger signal for autoimmune diseases. Frontiers in Immunology. 2017. 8: 598-598. DOI
13	Orosz E, Kiss I, Gyongyi Z, Varjas T. Expression of circulating mir-155, mir-21, mir-221, mir-30a, mir-34a and mir-29a: Comparison of colonic and rectal cancer. In Vivo. 2018. 32: 1333-1337. DOI
14	Pritchard CC, Cheng HH, Tewari M. Microrna profiling: Approaches and considerations. Nat Rev Genet. 2012. 13: 358-369. DOI
15	Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998. 66: 5224-5231. DOI
16	Yeol K. Colorectal cancer screening. Korean Journal of Family Practice. 2013. 3: 139-146.
17	Shi Q, Dai J, Huang L. Microrna-29a functions as a tumor suppressor in nasopharyngeal carcinoma 5-8f cells through targeting vegf. Iran J Basic Med Sci. 2019. 22: 541-546.
18	Tang B, Li X, Ren Y, Wang J, Xu D, Hang Y, Zhou T, Li F, Wang L. Microrna-29a regulates lipopolysaccharide (lps)-induced inflammatory responses in murine macrophages through the akt1/nf-κb pathway. Exp Cell Res. 2017. 360: 74-80. DOI
19	Wang J, Chen X, Xie C, Sun M, Hu C, Zhang Z, Luan L, Zhou J, Zhou J, Zhu X, Ouyang J, Dong X, Li D, Zhang J, Zhao X. Microrna mir-29a inhibits colon cancer progression by downregulating b7-h3 expression: Potential molecular targets for colon cancer therapy. Mol Biotechnol. 2021. 63: 849-861. DOI
20	Youden WJ. Index for rating diagnostic tests. Cancer. 1950. 3: 32-35. DOI
21	Zhu Y, Xu A, Li J, Fu J, Wang G, Yang Y, Cui L, Sun J. Fecal mir-29a and mir-224 as the noninvasive biomarkers for colorectal cancer. Cancer Biomark. 2016. 16: 259-264. DOI
22	Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC. Microrna expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008. 299: 425-436. DOI
23	Fukui H. Increased intestinal permeability and decreased barrier function: Does it really influence the risk of inflammation? Inflamm Intest Dis. 2016. 1: 135-145. DOI
24	Liu HN, Liu TT, Wu H, Chen YJ, Tseng YJ, Yao C, Weng SQ, Dong L, Shen XZ. Serum microrna signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods. Cancer Sci. 2018a. 109: 1185-1194. DOI
25	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. 71: 209-249. DOI
26	Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JFPanish JF et al. Prevention of colorectal cancer by colonoscopic polypectomy. The national polyp study workgroup. N Engl J Med. 1993. 329: 1977-1981. DOI
27	Wang J, Chen J, Sen S. Microrna as biomarkers and diagnostics. Journal of Cellular Physiology. 2016. 231: 25-30. DOI
28	Zheng Z, Cui H, Wang Y, Yao W. Downregulation of rps15a by mir-29a-3p attenuates cell proliferation in colorectal carcinoma. Biosci Biotechnol Biochem. 2019. 83: 2057-2064. DOI
29	Niedermaier T, Weigl K, Hoffmeister M, Brenner H. Diagnostic performance of flexible sigmoidoscopy combined with fecal immunochemical test in colorectal cancer screening: Meta-analysis and modeling. Eur J Epidemiol. 2017. 32: 481-493. DOI
30	Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020. 70: 145-164. DOI
31	Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, Higurashi T, Yukawa N, Amanuma Y, Kikuchi O, Muto M, Ueno Y, Nakajima A, Chiba T, Boland CR, Goel A. Serum mir-21, mir-29a, and mir-125b are promising biomarkers for the early detection of colorectal neoplasia. Clin Cancer Res. 2015. 21: 4234-4242. DOI